New HIV Data in LA ART
Studies of LA ART in People With Adherence Challenges or Viremia

Released: May 10, 2024

Expiration: May 09, 2025

Jonathan Appelbaum
Jonathan Appelbaum, MD, FACP, AAHIVS

Activity

Progress
1
Course Completed

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:

  • The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ART
  • Updates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48
  • The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutations